CSL Behring's Hemophilia B Drug May Have Dosing Advantage
FDA clears Idelvion, a long-acting recombinant albumin fusion protein, with potential to provide up to 14-day dosing; Biogen's Alprolix is dosed once weekly.
FDA clears Idelvion, a long-acting recombinant albumin fusion protein, with potential to provide up to 14-day dosing; Biogen's Alprolix is dosed once weekly.